Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

1.

Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.

Pardanani A, Verstovsek S.

Cancer J. 2007 Nov-Dec;13(6):384-91.

PMID:
18032976
[PubMed - indexed for MEDLINE]
2.

Primary eosinophilic disorders: a concise review.

Pardanani A, Tefferi A.

Curr Hematol Malig Rep. 2008 Jan;3(1):37-43. doi: 10.1007/s11899-008-0007-9. Review.

PMID:
20425445
[PubMed - indexed for MEDLINE]
3.

[Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].

Zhang Y, Yu MH, Xu SC, Yang L, Yu Y, Hao YS, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jan;29(1):3-8. Chinese.

PMID:
18512307
[PubMed - indexed for MEDLINE]
4.

Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.

Florian S, Esterbauer H, Binder T, Müllauer L, Haas OA, Sperr WR, Sillaber C, Valent P.

Leuk Res. 2006 Sep;30(9):1201-5. Epub 2006 Jan 6.

PMID:
16406018
[PubMed - indexed for MEDLINE]
5.

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.

Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A.

Br J Haematol. 2008 Dec;143(5):707-15. doi: 10.1111/j.1365-2141.2008.07294.x. Epub 2008 Oct 17.

PMID:
18950453
[PubMed - indexed for MEDLINE]
6.

[Mastocytosis and eosinophilic leukemia: diagnostics and classification].

Sotlar K, Valent P, Horny HP.

Pathologe. 2012 Nov;33(6):539-52. doi: 10.1007/s00292-012-1654-0. German.

PMID:
23085697
[PubMed - indexed for MEDLINE]
7.

[The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia].

Chrobák L, Voglová J.

Vnitr Lek. 2005 Dec;51(12):1385-93. Review. Czech.

PMID:
16430106
[PubMed - indexed for MEDLINE]
8.

Modern diagnosis and treatment of primary eosinophilia.

Tefferi A.

Acta Haematol. 2005;114(1):52-60. Review.

PMID:
15995325
[PubMed - indexed for MEDLINE]
9.

World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.

Gotlib J.

Am J Hematol. 2014 Mar;89(3):325-37. doi: 10.1002/ajh.23664. Review.

PMID:
24577808
[PubMed - indexed for MEDLINE]
10.

Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.

Yamada Y, Cancelas JA, Rothenberg ME.

Int Arch Allergy Immunol. 2009;149 Suppl 1:102-7. doi: 10.1159/000211381. Epub 2009 Jun 3. Review.

PMID:
19494514
[PubMed - indexed for MEDLINE]
11.

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.

Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU.

Allergy. 2009 Jun;64(6):913-8. doi: 10.1111/j.1398-9995.2009.01943.x. Epub 2009 Feb 7.

PMID:
19210352
[PubMed - indexed for MEDLINE]
12.

Hypereosinophilic syndrome: diagnosis and treatment.

Peros-Golubicić T, Smojver-Jezek S.

Curr Opin Pulm Med. 2007 Sep;13(5):422-7. Review.

PMID:
17940488
[PubMed - indexed for MEDLINE]
13.

Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients.

Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A.

Leuk Res. 2004 Aug;28(8):777-83.

PMID:
15203275
[PubMed - indexed for MEDLINE]
14.

[Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan].

Sada A, Matsui T.

Rinsho Ketsueki. 2010 Jul;51(7):515-25. Review. Japanese. No abstract available.

PMID:
20693771
[PubMed - indexed for MEDLINE]
15.

Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.

Dahabreh IJ, Giannouli S, Zoi C, Zoi K, Voulgarelis M, Moutsopoulos HM.

Medicine (Baltimore). 2007 Nov;86(6):344-54.

PMID:
18004179
[PubMed - indexed for MEDLINE]
16.

FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome.

Yamada Y, Sanchez-Aguilera A, Brandt EB, McBride M, Al-Moamen NJ, Finkelman FD, Williams DA, Cancelas JA, Rothenberg ME.

Blood. 2008 Sep 15;112(6):2500-7. doi: 10.1182/blood-2007-11-126268. Epub 2008 Jun 6.

PMID:
18539901
[PubMed - indexed for MEDLINE]
Free Article
17.

Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.

Gotlib J, Cross NC, Gilliland DG.

Best Pract Res Clin Haematol. 2006;19(3):535-69. Review.

PMID:
16781488
[PubMed - indexed for MEDLINE]
18.

Mastocytosis: pathology, genetics, and current options for therapy.

Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD.

Leuk Lymphoma. 2005 Jan;46(1):35-48. Review.

PMID:
15621779
[PubMed - indexed for MEDLINE]
19.

FIP1L1-PDGFRA positive chronic eosinophilic leukemia in Tunisian patients.

Menif S, Omri H, Hafsia R, Ben Romdhane N, Turki S, Meddeb B, Dellagi K.

Pathol Biol (Paris). 2007 Jun;55(5):242-5. Epub 2006 Nov 29.

PMID:
17137731
[PubMed - indexed for MEDLINE]
20.

[Two patients with hypereosinophilic syndrome].

van Ruth S, Lokhorst HM, Bruijnzeel-Koomen CA.

Ned Tijdschr Geneeskd. 2006 May 27;150(21):1193-7. Dutch.

PMID:
16768285
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk